65,437 trials
Pulmonary Disease, Chronic Obstructive
Primary: Internal Consistency (IC) of the Shortness of Breath With Daily Activities (SOBDA) Questionnaire in Participants With Chronic Obstructive Pulmonary Disease (COPD)…
Sinusitis
Primary: Presence of Mucus in the Paranasal Sinuses (Outcome Measure Percentage of Patients) — 71; 57; 33 percentage of patients — p=<0.05
Multiple Myeloma
Primary: Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment — 586; 519; 471; 340 participants
Tinea Cruris · Jock Itch
Primary: Percentage of Subjects — 25.3; 2.8 percentage of subjects with complete cur — p=0.025
Leukemia
Primary: Number of Participants With a Confirmed Response [Complete Response (CR) and Partial Response (PR)] on 2 Consecutive Evaluations at Least 4 Weeks Apart — 1 participants
Chronic Obstructive Pulmonary Disease
Primary: Number of Patients Who Were Cured — 91; 117 Participants — p=<0.05
Neuroendocrine Tumour With Carcinoid Symptoms
Primary: Subject Preference for Self or Partner Administration — 10; 12 participants
Bilateral Nasolabial Fold Wrinkles
Primary: Subject Wrinkle Assessment Responders — 57; 31 participants — p=.00001
Breast Cancer
Primary: Disease Response (Tumor Measurements)Per RECIST Criteria v. 2000 — 11; 14; 3 participants — p=0.95
HIV Infections · H1N1 Influenza Virus
Primary: The Number of Participants Who Had at Least One Adverse Event (AE) — 118; 11; 8; 0 Participants
Preterm Delivery · Short Cervix · Short Uterine Cervical Length
Primary: Number of Participants With Birth <=32 6/7 Weeks Gestation. — 36; 21 participants — p=0.020
Facial Wrinkles and Creases
Primary: Change in Subject Assessment of Wrinkles Compared to Baseline on Subject Wrinkle Assessment — 2; 5; 15; 11 participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Any Adverse Event (AE) — 33; 34; 38 participants
Seasonal Allergic Conjunctivitis
Primary: Bulbar Conjunctival Injection — -1.91; -1.71 units on a scale
Rhinitis, Allergic, Perennial
Primary: Cumulative Proportion (CU) of Participants (Par.) With an Event, as Measured as a Percentage, for Posterior Subcapsular Opacity (P) — 0.60; 0.88; 1.24; 1.84 Percentage…